hepatitis

Vardenafil (Vivanza) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

Vardenafil hydrochloride trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes

Apoptosis Inhibitor was a novel inhibitor of programmed cell death associate with caspase-3 inhibition.

Catalpol (Catalpinoside) is an iridoid glycoside with neuroprotective, anti-inflammatory, and anti-hepatitis virus effects.

Vardenafil dihydrochloride (Levitra) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

Hepatitis B Virus Pre-S Region (120-145) is a preS2 peptide that effectively blocks the attachment of single-chain Fv fragment (scFv) or IgG to recombinant Hepatitis B surface antigen (r-HBsAg) [1].

The hepatitis B virus (HBV) core protein has been found in the nucleus, the cytoplasm, or both of HBV-infected hepatocytes. nuclear localization of the HBV core protein is negatively regulated by phosphorylation during the cell cycle.

Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980), a synthetic peptide analog, specifically binds to Hep G2 cells and is a potential immunogen expected to induce protective antibodies through the attachment blockade pathway of virus neutralization [1] [2].

[Ala127] Hepatitis B Virus Pre-S Region (120-131) is a peptide with the sequence MQWNSTAFHQT, potentially useful for studies on activity enhancement [1].

The nucleocapsid of the hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a. The four major subtypes of HBsAg, adw, adr, ayw and ayr, are generated, and they have been proposed to

Hepatitis C Virus S5A 5B, a synthetic peptide substrate, replicates the NS5A 5B junction of the nonstructural protein (NS), serving as the substrate for examining HCV NS3 protease activity [1].

Hepatitis Virus C NS3 Protease Inhibitor 2, a peptide inhibitor derived from a product targeting the NS3 protease of the hepatitis C virus (HCV), exhibits inhibitory activity with a Ki value of 41 nM.

HBcAg (core antigen) is a hepatitis B viral protein. It is an indicator of active viral replication; this means the person infected with Hepatitis B can likely transmit the virus on to another person.

Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.

JTK-109 is an inhibitor of hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor and inhibits G1b and G3a subgenomic replicons and recombinant enzymes.

GS-6620 PM is a derivative of GS-6620, an orally administered anti-hepatitis C virus polymerase inhibitor and a novel potent C-nucleoside adenine analogue monophosphate prodrug.GS-6620 has limited activity against other viruses and maintains only partial activity against the closely related bovine viral diarrhea virus (EC50, 1.5 μM).

Uprifosbuvir (MK-3682) is a uridine nucleoside monophosphate prodrug inhibitor of hepatitis C virus NS5B RNA polymerase with antiviral activity for the study of chronic hepatitis C virus.

Metacavir (PNA) is a novel nucleoside reverse transcriptase inhibitor, a deoxyguanosine analog, with anti-hepatitis B virus (HBV) activity and mitochondrial toxicity, which can be used to study HBV infection.

Tivicilovir (AM188) is a hepatitis B virus inhibitor. tiviclovir is a guanine-related acyclic 2'-deoxyguanine analogue with anti-herpesvirus activity.

HBF-0259 is an inhibitors of hepatitis B virus surface antigen (HBsAg) secretion with an EC50 of 11.3 μM and a CC50 value of >50 μM in HepG2.2.15 cells. HBF-0259 had a EC50 of approximately 1.5 microM in a secondary, HBV-expressing cell line, with a concentration that exhibited 50% cytotoxicity of >50 microM. The equilibrium concentration of HBF-0259 in aqueous solution at physiological pH was 15 to 16 microM; the selective index was thus >9.

Adafosbuvir PM (AL-335 PM) is a small molecule NS5B inhibitor that can be used to study chronic hepatitis C.

Isatoribine(ANA245) free base is a potent TLR7 receptor agonist with anti-hepatitis C virus infection activity for the study of HCV infection.

IDX184 is a potent, orally active, targeted HCV polymerase inhibitor and nucleoside polymerase.IDX184 effectively inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM). IDX184 is a liver-targeted nucleotide prodrug with anti-HCV activity that inhibits HCV NS5B polymerase and can be used in combination with pegylated interferon-α2a and ribavirin for the primary treatment of chronic hepatitis C. It has been shown to inhibit HCV polymerase and nucleoside polymerase.